Braveheart Bio Inc. Common Stock

BRVE· NASDAQ· Health Care

$23.61-5.64%

2026-09-22

Valuation Metrics

Braveheart Bio Inc. Common Stock's Market Cap is $1.67B. Ranked #1995 of 3,119 in US market (top 64%), #759 of 1,463 on NASDAQ (top 52%) by Market Cap.

Investment Metrics(as of 2026-09-22)

Metric	Value	Rank
Size
Market Cap	$1.67B	US#1,995/3,119
Employees	30	US#2,750/3,119
Performance
1M Return	-14.39%	US#688/3,119
From 52W High	-26.22%	US#573/3,119
1Y MDD	-21.30%	US#455/3,119
Trading
Volume	829,221 shares	US#1,462/3,119
Trading Value	$20M	US#1,709/3,119

Company Info

CEO Travis Murdoch

Employees 30

HQ San Francisco, US

Website http://www.braveheart.bio

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.